Progenics Pharma (PGNX) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Progenics Pharmaceuticals Announces Third Quarter 2015 Financial Results
November 9, 2015 7:30 AM ESTTARRYTOWN, N.Y., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced results of operations for the quarter and nine months ended September 30, 2015.
We had a highly productive quarter, with positive regulatory developments, key additions to our pipeline and continued clinical progress, stated Mark Baker, CEO of Progenics. The Breakthrough Therapy Designation for ultra-orphan candidate AzedraTM provides for an expedited development and review process, while the April 2016 PDUFA date for Oral RELISTOR establishes a pivotal near-term catalyst for our RELISTOR franchise. We acquired PyL, an imaging agent which is highly complementary... More
